A Tel Aviv biotech building foundation models for antibody design, gene expression optimization, and virtual cell simulation in drug development.
Converge Bio
Released May 7, 2026
Virtual cell foundation model pretrained on over 23 million cells from 5,000 patient samples for drug target and biomarker discovery.